China Shineway Pharmaceutical Group Limited (C1S) - Total Liabilities
Based on the latest financial reports, China Shineway Pharmaceutical Group Limited (C1S) has total liabilities worth €2.72 Billion EUR (≈ $3.17 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore C1S net asset momentum to track the company's year-over-year net asset growth rate.
China Shineway Pharmaceutical Group Limited - Total Liabilities Trend (2013–2025)
This chart illustrates how China Shineway Pharmaceutical Group Limited's total liabilities have evolved over time, based on quarterly financial data. See C1S cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
China Shineway Pharmaceutical Group Limited Competitors by Total Liabilities
The table below lists competitors of China Shineway Pharmaceutical Group Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu LiXing General Steel Ball Co Ltd
SHE:300421
|
China | CN¥664.69 Million |
|
Daoming Optics&Chemical Co Ltd
SHE:002632
|
China | CN¥710.12 Million |
|
Magic Software Enterprises Ltd
TA:MGIC
|
Israel | ILA258.98 Million |
|
Nuveen Select Tax-Free Income Portfolio
NYSE:NXP
|
USA | $32.02 Million |
|
Yang Guang Co Ltd
SHE:000608
|
China | CN¥1.77 Billion |
|
Burelle SA
PA:BUR
|
France | €5.68 Billion |
|
Obsidian Energy Ltd
TO:OBE
|
Canada | CA$613.70 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down China Shineway Pharmaceutical Group Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see China Shineway Pharmaceutical Group Limi (C1S) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China Shineway Pharmaceutical Group Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China Shineway Pharmaceutical Group Limited (2013–2025)
The table below shows the annual total liabilities of China Shineway Pharmaceutical Group Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.72 Billion ≈ $3.17 Billion |
+5.46% |
| 2024-12-31 | €2.57 Billion ≈ $3.01 Billion |
+1.39% |
| 2023-12-31 | €2.54 Billion ≈ $2.97 Billion |
+37.30% |
| 2022-12-31 | €1.85 Billion ≈ $2.16 Billion |
+41.99% |
| 2021-12-31 | €1.30 Billion ≈ $1.52 Billion |
-8.23% |
| 2020-12-31 | €1.42 Billion ≈ $1.66 Billion |
+4.79% |
| 2019-12-31 | €1.35 Billion ≈ $1.58 Billion |
+40.21% |
| 2018-12-31 | €966.01 Million ≈ $1.13 Billion |
+14.43% |
| 2017-12-31 | €844.16 Million ≈ $986.91 Million |
+0.66% |
| 2016-12-31 | €838.59 Million ≈ $980.40 Million |
-2.16% |
| 2015-12-31 | €857.13 Million ≈ $1.00 Billion |
-15.50% |
| 2014-12-31 | €1.01 Billion ≈ $1.19 Billion |
-22.49% |
| 2013-12-31 | €1.31 Billion ≈ $1.53 Billion |
-- |
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more